Anna Baraldi

Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma

Michèle Cavo, Lucia Pantani, Maria Teresa Petrucci et al. · Blood · 2012 · 309 citations · Full text

Medicine, Hematology, Pharmacotherapy +16

Hairy cell leukemias with unmutated IGHV genes define the minor subset refractory to single-agent cladribine and with more aggressive behavior

Francesco Forconi, Elisa Sozzi, Emanuele Cencini et al. · Blood · 2009 · 132 citations · Full text

Medicine, Genetics, Oncology +6

<scp>E</scp>pstein–<scp>B</scp>arr virus reactivation in allogeneic stem cell transplantation is highly related to cytomegalovirus reactivation

Francesco Zallio, Valeria Primon, Stefania Tamiazzo et al. · Clinical Transplantation · 2013 · 59 citations

Life Sciences, Hematology, Immunology +13

Carfilzomib-Lenalidomide-Dexamethasone (KRd) Induction-Autologous Transplant (ASCT)-Krd Consolidation Vs KRd 12 Cycles Vs Carfilzomib-Cyclophosphamide-Dexamethasone (KCd) Induction-ASCT-KCd Consolidation: Analysis of the Randomized Forte Trial in Newly Diagnosed Multiple Myeloma (NDMM)

Francesca Gay, Chiara Cerrato, Delia Rota Scalabrini et al. · Blood · 2018 · 54 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Hematologic improvement and response in elderly AML/RAEB patients treated with valproic acid and low-dose Ara-C

Maria Teresa Corsetti, Flavia Salvi, Sonia Perticone et al. · Leukemia Research · 2011 · 48 citations

Medicine, Hematology, Pharmacotherapy +10